Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Chronic Lymphocytic Leukemia

Breast Cancer

Gastrointestinal Cancer

Colorectal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Chronic Lymphocytic Leukemia

Novel Agents Show Enhanced Efficacy Across CLL Subtypes

Matthew S. Davids, MD, MMSc, discusses recent shifts in the chronic lymphocytic leukemia paradigm with the use of novel therapies and the need to increase personalized treatment with these agents.
Read More >>

Fee-for-Service Unlikely to Disappear Soon

Progress in Relapsed/Refractory CLL Could Pave Way for Upfront Advances

Experts Dissect 3 Practice-Changing Studies for Newly Diagnosed CLL

Novel Regimens Take Precedence in Newly Diagnosed CLL

FDA Approval Sought for Venetoclax/Obinutuzumab Combo for Frontline CLL

View More Stories >>

View Conference Coverage

2019 State of the Science Summit on Hematologic Malignancies in Wisconsin

2019 European Lung Cancer Congress

2019 NCCN Annual Conference

2019 State of the Science Summit on Hematologic Malignancies

2019 SGO Annual Meeting

Dr. Barrientos Discusses Promising Agents in CLL

Dr. Davids on Frontline Challenges in CLL

$Dr. Wierda on Novel Therapies in Relapsed/Refractory CLL$

Dr. Wierda on Novel Therapies in Relapsed/Refractory CLL

Dr. Davids Discusses Frontline Approaches in CLL

Dr. Seymour on Promising Combinations in CLL

$Dr. Wierda on Treatment of Relapsed/Refractory CLL$

Dr. Jacobs on Treating Graft-Versus-Host-Disease With Ibrutinib in CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

Resistance to Venetoclax in CLL

CD20-Targeted Antibodies With Novel Agents for CLL

Toxicity Management With Venetoclax for CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

BTK Inhibitors in Chronic Lymphocytic Leukemia

Genomic Profiling in Chronic Lymphocytic Leukemia

Venetoclax-Based Regimens as First-Line Therapy in CLL

$Relapsed/Refractory CLL: Evaluating Other Novel Agents$

$Novel Approaches to Treating Relapsed/Refractory CLL$

$Continuing Therapy in Relapsed/Refractory CLL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Other Promising Strategies in CLL

This expert panel discussion led by William Wierda, MD, focuses on promising strategies available for the treatment of chronic lymphocytic leukemia. Dr. Wierda is joined in this discussion by Steven Coutre, MD; Matthew S. Davids, MD, MMSc; Nicole Lamanna, MD; and Shuo Ma, MD, PhD.